SBIR AND STTR FUNDING
OPPORTUNITIES
OPPORTUNITIES
Non-dilutive funding for early-stage research and development.
[Omnibus Solicitations] [Specific Opportunities]
SBIR and STTR grant funding opportunities offer small business entrepreneurs a chance to obtain non-dilutive funding for early-stage research and development. Applications are accepted three times a year.
NIH advertises the availability of grant support through notices of funding opportunities (NOFOs), previously referred to as funding opportunity announcements (FOAs).
More information on HHS SBIR contracts is available on the NIH SBIR contracts webpage.
Helpful Tips
- Follow these step-by-step instructions to learn how to apply for these funding opportunities, including resources on how to prepare your application.
- Read Program Descriptions and Research Topics.
- Refer to SBA-approved waiver eligible topics.
- Watch this NIH SBIR/STTR webinar from June 2025.
Omnibus Solicitations (Parent Announcements)
Researcher-initiated ideas are proposed via the SBIR and STTR Omnibus grant solicitations. These funding opportunities do not specify a topic, though they link to identified topics of interest for each participating awarding component. Most small business applications to NIH are submitted to the Omnibus solicitations.
Read the Program Descriptions and Research Topics to understand the awarding components, their topics of interest, and staff contacts. For topics that require additional funding to reach the marketplace, please refer to our list of SBA-approved waiver-eligible topics.
Standard Application Due Dates are September 5, January 5, and April 5. Due dates that fall on weekends or Federal holidays are moved to the next business day.
No SBIR/STTR Omnibus Solicitations (Parent Announcements) found.
Specific Funding Opportunities
Some SBIR/STTR grant solicitations are focused on specific research areas. Some specific NOFOs, identified as RFAs (Requests for Applications) or PASs (Program Announcements with Set-aside funds), have funding set-aside in the Institute/Center's budget for that targeted program.
| Title | Notice/FOA Number | Organization | Release Date | Due Date(s) | Expiration Date | Clinical Trials |
|---|---|---|---|---|---|---|
| Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional) | PAR-24-098 | NINDS | 01/22/2024 | Multiple dates, see announcement....(see announcement for full details) | 06/26/2026 | Optional |
| Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional) | PAR-24-294 | NINDSNCCIHNEINIANIAAANIDANIDCRNIEHSNIMHOBSSR | 10/01/2024 | Multiple dates, see announcement....(see announcement for full details) | 08/19/2027 | Optional |
| Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional) | PAR-24-063 | NINDSNCCIHNEINIANIAAANICHDNIDANIDCRNIMHOBSSR | 11/01/2023 | 08/19/2026 | Optional | |
| Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional) | PAR-24-096 | NINDS | 01/22/2024 | Multiple dates, see announcement....(see announcement for full details) | 06/23/2026 | Optional |
| Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional) | RFA-MD-24-006 | NIMHDNCATSNHLBINIANIBIBNIDCRNIDDKNINDSNINR | 03/08/2024 | Multiple dates, see announcement....(see announcement for full details) | 12/10/2026 | Optional |
| Miniaturization and Automation of Tissue Chip Systems (MATChS) (U43/U44 Clinical Trial Not Allowed) | RFA-TR-23-017 | NCATS | 11/21/2023 | Multiple dates, see announcement....(see announcement for full details) | 09/05/2026 | Not Allowed |
| Miniaturization and Automation of Tissue Chip Systems (MATChS) (UT1/UT2 - Clinical Trial Not Allowed) | RFA-TR-23-018 | NCATS | 11/21/2023 | Multiple dates, see announcement....(see announcement for full details) | 09/05/2026 | Not Allowed |
| NEI Small Business Innovation Research (SBIR) Cooperative Agreement for Early-Stage Clinical Trials with Greater than Minimal Risk (U44-Clinical Trial Required) | PAR-24-066 | NEI | 12/01/2023 | Multiple dates, see announcement....(see announcement for full details) | 01/08/2027 | Required |
| NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional) | PAR-25-133 | NINDS | 11/12/2024 | Multiple dates, see announcement....(see announcement for full details) | 09/06/2027 | Optional |
| NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) | RFA-HL-26-014 | NHLBI | 11/18/2024 | Not Applicable...(see announcement for full details) | 02/27/2027 | Optional |
| NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) | RFA-HL-26-015 | NHLBINCATS | 11/18/2024 | Not Applicable...(see announcement for full details) | 02/27/2027 | Optional |
| NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required) | PAR-24-099 | NIAID | 01/29/2024 | Multiple dates, see announcement....(see announcement for full details) | 01/14/2027 | Required |
| NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required) | PAR-24-044 | NINDS | 11/27/2023 | Multiple dates, see announcement....(see announcement for full details) | 09/06/2026 | Required |
| NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required) | PAR-23-311 | NINDS | 11/27/2023 | Multiple dates, see announcement....(see announcement for full details) | 09/06/2026 | Required |
| NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Clinical Trials and Clinical Research (R44 Clinical Trial Optional) | PAR-24-221 | NINDS | 06/20/2024 | Multiple dates, see announcement....(see announcement for full details) | 04/06/2027 | Optional |
| NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Pre-Clinical Research (R44 Clinical Trial Not Allowed) | PAR-24-222 | NINDS | 06/21/2024 | Not Applicable...(see announcement for full details) | 04/06/2027 | Not Allowed |
| Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional) | RFA-DA-25-047 | NIDA | 09/28/2023 | 03/14/2026 | Optional | |
| Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional) | RFA-DA-25-048 | NIDA | 09/28/2023 | 03/14/2026 | Optional | |
| Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed) | PAR-24-133 | NIHNCATSNCCIHNEINHGRINHLBINIANIAAANIAMSNICHDNIDANIDCDNIDCRNIEHSNIGMSNINRNLM | 04/25/2024 | Multiple dates, see announcement....(see announcement for full details) | 04/06/2027 | Not Allowed |
| Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Required) | PAR-24-134 | NIHNCCIHNEINHGRINHLBINIANIAAANICHDNIDANIDCDNINRNLM | 04/25/2024 | Multiple dates, see announcement....(see announcement for full details) | 04/06/2027 | Required |
| Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Not Allowed) | PAR-24-131 | NIHNCATSNCCIHNEINHGRINHLBINIANIAAANIAMSNICHDNIDANIDCDNIDCRNIDDKNIEHSNIGMSNINRNIOSHNLM | 04/25/2024 | Multiple dates, see announcement....(see announcement for full details) | 04/06/2027 | Not Allowed |
| Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Required) | PAR-24-132 | NIHNCCIHNEINHGRINHLBINIANIAAANICHDNIDANIDCDNINRNIOSHNLM | 04/26/2024 | Multiple dates, see announcement....(see announcement for full details) | 04/06/2027 | Required |
| Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional) | RFA-MD-24-007 | NIMHDNCATSNIBIBNIDCRNINDSNINR | 03/08/2024 | Multiple dates, see announcement....(see announcement for full details) | 12/10/2026 | Optional |
